Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
- 1 November 2004
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 324 (1) , 92-97
- https://doi.org/10.1016/j.bbrc.2004.09.021
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2003
- Natural Substrates of Dipeptidyl Peptidase IVPublished by Springer Nature ,2002
- Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic SubjectsDiabetes Care, 2001
- Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26Proceedings of the National Academy of Sciences, 2000
- Effect of metformin on patients with impaired glucose toleranceDiabetic Medicine, 1999
- Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine ThiazolidideDiabetes, 1998
- Glibenclamide: an old drug with a novel mechanism of action?Acta Diabetologica, 1997
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)Journal of Biological Chemistry, 1995
- The role of ion channels in insulin secretionJournal of Cellular Biochemistry, 1992
- Mechanism of Metformin Action in Obese and Lean Noninsulin-Dependent Diabetic Subjects*Journal of Clinical Endocrinology & Metabolism, 1991